- Home
- SEE vs PTGX Comparison
SEE vs PTGX Comparison
Compare SEE & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$41.95
HOLD
Current Price
$82.05
Company Overview
Basic Information| Metric | SEE | PTGX |
|---|---|---|
| Founded | 1960 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.1B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SEE | PTGX |
|---|---|---|
| Price | $41.95 | $82.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $43.50 | ★ $99.20 |
| AVG Volume (30 Days) | ★ 2.7M | 755.5K |
| Earning Date | 03-02-2026 | 02-20-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 13.73 | N/A |
| EPS | ★ 3.09 | 0.72 |
| Revenue | ★ $5,331,600,000.00 | $209,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.16 | $462.10 |
| P/E Ratio | ★ $13.55 | $115.92 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.78 | $33.70 |
| 52 Week High | $44.27 | $96.54 |
Technical Indicators
Market Signals| Indicator | SEE | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 61.89 | 46.67 |
| Support Level | $41.75 | $80.99 |
| Resistance Level | $41.91 | $84.90 |
| Average True Range (ATR) | 0.10 | 3.39 |
| MACD | -0.02 | 0.15 |
| Stochastic Oscillator | 78.00 | 53.15 |
Price Performance
Historical Comparison SEE
PTGX
About SEE Sealed Air Corporation
Sealed Air is organized via two reporting segments. Food includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Protective includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.